8-KThe WireRoutine
Reg FD Disclosure
Filed Apr 20, 2026 · 2mo ago · Accession 0001104659-26-045219
Plain English
Passage Bio, Inc. announced updated interim data from its PBFT02 clinical trial and initiated a review of strategic alternatives, which may include a merger, acquisition, or sale of assets.
Filing details
- Company
- Passage BIO, Inc.
- Ticker
- PASG
- CIK
- 1787297
- Form type
- 8-K
- Filing date
- Apr 20, 2026
- Report date
- Apr 20, 2026
- Document
- tm2612152d1_8k.htm
- Size
- 6.0 MB